International Journal of Biology Pharmacy and Allied Sciences,
Год журнала:
2021,
Номер
10(12)
Опубликована: Ноя. 30, 2021
Resealed
erythrocyte
is
novel
drug
delivery
system
mainly
used
for
targeting
specific
tissues
with
drug.This
having
number
of
advantages
over
the
other
in
case
diseases
like
cancer.There
are
various
methods
preparation
resealed
erythrocyte.In
this
study,
we
have
prepared
erythrocytes
by
two
techniques,
Dilution
technique
and
preswell
dilution
adding
cross
linking
agent,
glutaraldehyde
due
to
which
%
encapsulation
efficiency
was
increased
results
were
obtained.With
these
results,
found
that,
vitro
release
followed
first
order
kinetics
sustained
release.The
more
formulations
as
compared
technique.The
hematological
parameters
satisfactory.The
particle
size,
zeta
potential,
osmotic
shock,
fragility,
turbulent
shock
studies,
stability
study
tested
optimized
formulations.This
has
exclusive
conventional
systems
hence
proved
be
potential
clinical
point
view.
ACS Biomaterials Science & Engineering,
Год журнала:
2015,
Номер
1(4), С. 201 - 217
Опубликована: Март 12, 2015
Drug
delivery
systems,
particularly
nanomaterial-based
drug
possess
a
tremendous
amount
of
potential
to
improve
diagnostic
and
therapeutic
effects
drugs.
Controlled
targeted
specific
disease
is
designed
significantly
the
pharmaceutical
drugs
reduce
their
side
effects.
Unfortunately,
only
few
systems
can
achieve
high
targeting
efficiency
after
intravenous
injection,
even
with
development
numerous
surface
markers
modalities.
Thus,
alternative
nanomedicine
approaches
are
desired.
Circulating
cells,
such
as
erythrocytes,
leukocytes,
stem
present
innate
sensing
homing
properties.
Hence,
using
living
cells
carriers
has
gained
increasing
interest
in
recent
years.
This
review
highlights
advances
design
cell-mediated
mechanisms.
The
encapsulation/conjugation
cell-carriers,
mechanisms,
methods
controlled
release
elaborated
here.
Cell-based
"live"
could
be
used
facilitate
more
specific,
robust,
smart
payload
distribution
for
next-generation
systems.
Pharmaceutics,
Год журнала:
2020,
Номер
12(3), С. 276 - 276
Опубликована: Март 18, 2020
Drug
delivery
using
natural
biological
carriers,
especially
erythrocytes,
is
a
rapidly
developing
field.
Such
erythrocytes
can
act
as
carriers
that
prolong
the
drug's
action
due
to
its
gradual
release
from
carrier;
bioreactors
with
encapsulated
enzymes
performing
necessary
reactions,
while
remaining
inaccessible
immune
system
and
plasma
proteases;
or
tool
for
targeted
drug
target
organs,
primarily
cells
of
reticuloendothelial
system,
liver
spleen.
To
date,
have
been
studied
wide
range
drugs,
such
enzymes,
antibiotics,
anti-inflammatory,
antiviral
etc.,
diagnostic
purposes
(e.g.
magnetic
resonance
imaging).
The
review
focuses
only
on
drugs
loaded
inside
defines
main
lines
research
bioactive
substances,
well
advantages
limitations
their
application.
Particular
attention
paid
in
vivo
studies,
opening-up
potential
clinical
use
into
erythrocytes.
Drug Design Development and Therapy,
Год журнала:
2016,
Номер
unknown, С. 665 - 665
Опубликована: Фев. 1, 2016
Abstract:
Erythrocyte
drug
encapsulation
is
one
of
the
most
promising
therapeutic
alternative
approaches
for
administration
toxic
or
rapidly
cleared
drugs.
Drug-loaded
erythrocytes
can
operate
through
three
main
mechanisms
action:
extension
circulation
half-life
(bioreactor),
slow
release,
specific
organ
targeting.
Although
clinical
development
erythrocyte
carriers
confronted
with
regulatory
and
process
challenges,
industrial
expanding.
The
manufacture
this
type
product
be
either
centralized
bedside
based,
different
procedures
are
employed
agents.
major
challenges
successful
industrialization
include
production
scalability,
validation,
quality
control
released
Advantages
drawbacks
manufacturing
processes
as
well
success
key
points
discussed.
Several
entrapment
technologies
based
on
osmotic
methods
have
been
industrialized.
Companies
already
achieved
many
critical
stages,
thus
providing
opportunity
in
future
to
cover
a
wide
range
diseases
which
effective
therapies
not
currently
available.
Keywords:
red
blood
cell,
method,
carrier,
development,
use
Pharmaceutics,
Год журнала:
2022,
Номер
14(9), С. 1820 - 1820
Опубликована: Авг. 29, 2022
As
one
of
the
most
frequent
complications
critical
illness,
acute
lung
injury
(ALI)
carries
a
high
risk
clinical
morbidity
and
mortality.
Cepharanthine
(CPA)
has
significant
anti-inflammatory
activity,
however,
due
to
poor
water
solubility,
low
bioavailability,
short
half-life,
it
fails
provide
effective
management
measures.
Here,
we
explored
flexibility
an
erythrocyte-anchoring
strategy
using
CPA-encapsulated
chitosan-coating
nanoparticles
(CPA-CNPs)
anchored
onto
circulating
erythrocytes
for
treatment
ALI.
CPA-CNPs
adhered
successfully
(E-CPA-CNPs)
exhibited
erythrocyte
adhesion
efficiency
(>80%).
Limited
toxicity
favorable
biocompatibility
enabled
further
application
E-CPA-CNPs.
Next,
reticuloendothelial
system
evasion
features
were
analyzed
in
RAW264.7
macrophages
Sprague-Dawley
rats.
Compared
with
bare
CPA-CNPs,
erythrocyte-anchored
CNPs
significantly
decreased
cellular
uptake
immune
cells
prolonged
circulation
time
vivo.
Notably,
be
delivered
accumulated
lungs
(up
6-fold).
In
ALI
mouse
model,
E-CPA-CNPs
attenuated
progression
by
inhibiting
inflammatory
responses.
Overall,
our
results
demonstrate
outstanding
advantages
improving
pharmacokinetics
bioavailability
CPA,
which
offers
great
promise
lung-targeted
drug
delivery
